Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Non-Current Deffered Revenue (2016 - 2017)

Coherus Oncology's Non-Current Deffered Revenue history spans 5 years, with the latest figure at $725000.0 for Q1 2017.

  • For Q1 2017, Non-Current Deffered Revenue fell 97.8% year-over-year to $725000.0; the TTM value through Mar 2017 reached $725000.0, down 97.8%, while the annual FY2016 figure was $669000.0, 98.52% down from the prior year.
  • Non-Current Deffered Revenue for Q1 2017 was $725000.0 at Coherus Oncology, up from $669000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $45.3 million in Q4 2015 and bottomed at $595000.0 in Q3 2016.
  • The 5-year median for Non-Current Deffered Revenue is $33.2 million (2015), against an average of $27.1 million.
  • The largest annual shift saw Non-Current Deffered Revenue surged 39.67% in 2014 before it crashed 98.52% in 2016.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $28.6 million in 2013, then skyrocketed by 39.67% to $39.9 million in 2014, then increased by 13.63% to $45.3 million in 2015, then plummeted by 98.52% to $669000.0 in 2016, then increased by 8.37% to $725000.0 in 2017.
  • Per Business Quant, the three most recent readings for CHRS's Non-Current Deffered Revenue are $725000.0 (Q1 2017), $669000.0 (Q4 2016), and $595000.0 (Q3 2016).